For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Expansion of Business into Turkey and India

Tokyo, May 13, 2008 - DAIICHI SANKYO COMPANY, LIMITED announced today that its subsidiary DAIICHI SANKYO Europe GmbH has established the Turkish subsidiary DAIICHI SANKYO Ilaç, Ticaret Ltd.Şti. in Istanbul. This company will play a part in the DAIICHI SANKYO group's European business operations under the supervision of DAIICHI SANKYO Europe GmbH of Munich, Germany which is the headquarters for 11 European markets. The business of this company will initially focus on sales of Evista (generic name: raloxifen hydrochloride), the medication for the treatment of osteoporosis in postmenopausal women.

DAIICHI SANKYO also announced that it signed a co-promotion agreement with Glaxo Smith Kline Pharmaceuticals Limited for the antihypertensive agent Benitec(TM)(generic name:
olmesartan medoxomil) in India. Sales of the drug are to start in June 2008. DAIICHI SANKYO established its India subsidiary Daiichi Sankyo India Pharma Private Limited in Mumbai in March 2007 which is currently in the process of expanding its operational structure to start full-scale
business.